Aleksandra Budnicka
Aleksandra Budnicka has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A. Przybysz
Department of Gastroenterological Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
1 shared publication - Andrzej Białek
Department of Gastroenterology, Pomeranian Medical University in Szczecin, Szczecin, Poland
1 shared publication - Jaroslaw Regula
Department of Oncological Gastroenterology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publication - Michal F. Kaminski
Cancer Prevention Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publication - Michal Filip Kaminski
Department of Oncological Gastroenterology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publication - Michał Spychalski
Center of Bowel Treatment, 95-060 Brzeziny, Poland
1 shared publication
Latest Publications
- 8 August 2024
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 71, 101943
Traditional septotomy or Z-POEM for Zenker's diverticulum
- 8 August 2024
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 71, 101943
Traditional septotomy or Z-POEM for Zenker's diverticulum
- Open Access
- 7 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 187
Peroral Endoscopic Myotomy in the Management of Zenker’s Diverticulum: A Retrospective Multicenter Study
Background: Peroral endoscopic myotomy (POEM) is an emerging technique in the treatment of Zenker’s diverticulum (ZD). This study aimed to analyze the feasibility of Zenker’s POEM (Z-POEM) in a multicenter setting and assess its performance using a validated Kothari-Haber Scoring System newly developed for symptom measurement in ZD. Materials and methods: This was a multicenter retrospective study involving three Polish tertiary referral endoscopic units. The data of consecutive patients with symptomatic ZD treated with Z-POEM in Poland between May 2019 and August 2020 were retrieved and analyzed. Primary outcome measures were technical success and clinical success rate (p < 0.0001). The mean procedure time was 48.8 (±19.3) minutes, and the median length of hospital stay was 2 days (IQR, 2–3). Three patients (13.6%) had post-procedural emphysema, of which two were mild and self-resolving (9.1%), and one was moderate (4.5%) and complicated with laryngeal edema and prolonged intubation. Conclusions: This feasibility study suggests that Z-POEM is a highly effective and safe treatment for ZD, particularly among treatment-naïve patients. Comparative studies with other treatment modalities over longer follow-up are warranted.
- 7 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 187
Open AccessPeroral Endoscopic Myotomy in the Management of Zenker’s Diverticulum: A Retrospective Multicenter Study
Background: Peroral endoscopic myotomy (POEM) is an emerging technique in the treatment of Zenker’s diverticulum (ZD). This study aimed to analyze the feasibility of Zenker’s POEM (Z-POEM) in a multicenter setting and assess its performance using a validated Kothari-Haber Scoring System newly developed for symptom measurement in ZD. Materials and methods: This was a multicenter retrospective study involving three Polish tertiary referral endoscopic units. The data of consecutive patients with symptomatic ZD treated with Z-POEM in Poland between May 2019 and August 2020 were retrieved and analyzed. Primary outcome measures were technical success and clinical success rate (p < 0.0001). The mean procedure time was 48.8 (±19.3) minutes, and the median length of hospital stay was 2 days (IQR, 2–3). Three patients (13.6%) had post-procedural emphysema, of which two were mild and self-resolving (9.1%), and one was moderate (4.5%) and complicated with laryngeal edema and prolonged intubation. Conclusions: This feasibility study suggests that Z-POEM is a highly effective and safe treatment for ZD, particularly among treatment-naïve patients. Comparative studies with other treatment modalities over longer follow-up are warranted.